ASKC202+ Limertinib

Phase 3Small molecule

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

ASKC202+ Limertinib is one of 17 small molecule programs targeting Locally Advanced or Metastatic NSCLC. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced or Metastatic NSCLCRecruiting

Locally Advanced or Metastatic NSCLCPhase 3

Recruiting

Competition

Competitive Landscape

17 competitors in Locally Advanced or Metastatic NSCLC

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 3

5 2

Tecentriq

Roche

Phase 2

1 3

Lumakras

Amgen

Phase 2

1 4

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 3

2 5

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

2 6

Vebreltinib

AAvistone Biotechnology Co., Ltd.

Phase 3

2 7

SYS6010

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

1 8

Disitamab Vedotin

Pfizer

Phase 2

1 9

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 2

1 10

ASK120067

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Locally Advanced or Metastatic NSCLC

NCT07109531

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic NSCLC1 trial

A Randomized, Controlled, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of ASKC202 in Combination With Limertinib Versus Platinum-based Chemotherapy in Participants With MET Amplification/Overexpression Locally Advanced or Metastatic NSCLC Who Have Failed After Prior EGFR-TKI Therapy.

Recruiting·JJiangsu Aosaikang Pharmaceutical Co., Ltd.·Phase 3·NCT07109531·286 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ASKC202+ Limertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASKC202+ Limertinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASKC202+ Limertinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Aosaikang Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu Aosaikang Pharmaceutical Co., Ltd.

ASKC202+ Limertinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Locally Advanced or Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News